BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cozijnsen MA, Escher JC, Griffiths A, Turner D, de Ridder L. Benefits and Risks of Combining Anti-tumor Necrosis Factor with Immunomodulator Therapy in Pediatric Inflammatory Bowel Disease. Inflamm Bowel Dis. 2015;21:951-961. [PMID: 25723615 DOI: 10.1097/mib.0000000000000245] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.9] [Reference Citation Analysis]
Number Citing Articles
1 Kammermeier J, Morris MA, Garrick V, Furman M, Rodrigues A, Russell RK. Management of Crohn’s disease. Arch Dis Child. 2016;101:475-480. [PMID: 26553907 DOI: 10.1136/archdischild-2014-307217] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
2 Cozijnsen MA, van Pieterson M, Samsom JN, Escher JC, de Ridder L. Top-down Infliximab Study in Kids with Crohn's disease (TISKids): an international multicentre randomised controlled trial. BMJ Open Gastroenterol 2016;3:e000123. [PMID: 28090335 DOI: 10.1136/bmjgast-2016-000123] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.5] [Reference Citation Analysis]
3 Guariso G, Gasparetto M. Treating children with inflammatory bowel disease: Current and new perspectives. World J Gastroenterol 2017; 23(30): 5469-5485 [PMID: 28852307 DOI: 10.3748/wjg.v23.i30.5469] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 21] [Article Influence: 4.8] [Reference Citation Analysis]
4 Lee KM, Kim YS, Seo GS, Kim TO, Yang SK; IBD Study Group of the Korean Association for the Study of Intestinal Diseases. Use of Thiopurines in Inflammatory Bowel Disease: A Consensus Statement by the Korean Association for the Study of Intestinal Diseases (KASID). Intest Res. 2015;13:193-207. [PMID: 26130993 DOI: 10.5217/ir.2015.13.3.193] [Cited by in Crossref: 39] [Cited by in F6Publishing: 40] [Article Influence: 5.6] [Reference Citation Analysis]
5 Choi J, Kang B, Kim MJ, Sohn I, Lee HJ, Choe YH. Early Infliximab Yields Superior Long-Term Effects on Linear Growth in Pediatric Crohn's Disease Patients. Gut Liver 2018;12:255-62. [PMID: 29298460 DOI: 10.5009/gnl17290] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
6 Navas-lópez VM, Pujol-muncunill G, Llerena E, Navalón Rubio M, Gil-ortega D, Varea-calderón V, Sierra Salinas C, Martin-de-carpi J. A real-world study focused on the effectiveness and safety of adalimumab as first-line anti-TNF treatment for paediatric Crohn's disease. Anales de Pediatría (English Edition) 2018;88:89-99. [DOI: 10.1016/j.anpede.2017.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Kang B, Choe YH. Early Biologic Treatment in Pediatric Crohn's Disease: Catching the Therapeutic Window of Opportunity in Early Disease by Treat-to-Target. Pediatr Gastroenterol Hepatol Nutr 2018;21:1-11. [PMID: 29383299 DOI: 10.5223/pghn.2018.21.1.1] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
8 Choi SY, Kang B. Adalimumab in Pediatric Inflammatory Bowel Disease. Front Pediatr 2022;10:852580. [DOI: 10.3389/fped.2022.852580] [Reference Citation Analysis]
9 Cozijnsen MA, Samsom JN, de Ridder L. Anti-Tumour Necrosis Factor Therapy for Paediatric Crohn's Disease: Improved Benefits Through Treatment Optimisation, Deeper Understanding of Its Risks, and Reduced Costs due to Biosimilar Availability. Paediatr Drugs 2018;20:19-28. [PMID: 29079905 DOI: 10.1007/s40272-017-0266-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
10 Herfarth HH, Long MD, Isaacs KL. Use of Biologics in Pouchitis: A Systematic Review. J Clin Gastroenterol. 2015;49:647-654. [PMID: 26084005 DOI: 10.1097/mcg.0000000000000367] [Cited by in Crossref: 42] [Cited by in F6Publishing: 10] [Article Influence: 7.0] [Reference Citation Analysis]